Antibodies targeted to the brain with image-guided focused ultrasound reduces amyloid-β plaque load in the TgCRND8 mouse model of Alzheimer's disease

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Jordão, Jessica F ^a,b   Ayala Grosso, Carlos A ^a,d   Markham, Kelly ^a   Huang, Yuexi ^a   Chopra, Rajiv ^a,b   McLaurin, JoAnne ^b,c   Hynynen, Kullervo ^a,b   Aubert, Isabelle ^a,b  

^a Sunnybrook Health Sciences Centre   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; GADOBUTROL; PERFLUTREN; ANTIBODY;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CORTEX; BRAIN REGION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG PENETRATION; DRUG TARGETING; DRUG TISSUE LEVEL; FEMALE; HIGH INTENSITY FOCUSED ULTRASOUND; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN DETERMINATION; RESPONSE TIME; TREATMENT RESPONSE; ANIMAL; BRAIN; DISEASE MODEL; ECHOENCEPHALOGRAPHY; ECHOGRAPHY; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; PATHOLOGY; PERMEABILITY; SENILE PLAQUE; TIME; TRANSGENIC MOUSE;

MUS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES; BLOOD-BRAIN BARRIER; BRAIN; DISEASE MODELS, ANIMAL; ECHOENCEPHALOGRAPHY; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MICE; MICE, TRANSGENIC; PERMEABILITY; SENILE PLAQUES; TIME FACTORS;

EID: 77956287949     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010549     Document Type: Article

References (29)

1. Weiner HL, Frenkel D (2006) Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 6: 404-416.
2. Hawkes CA, McLaurin J (2007) Immunotherapy as treatment for Alzheimer's disease. Expert Rev Neurother 7: 1535-1548.
3. Thakker DR, Weatherspoon MR, Harrison J, Keene TE, Lane DS, et al. (2009) Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. Proc Natl Acad Sci USA 106: 4501-4506.
4. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, et al. (2002) Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 22: 6331-6335.
5. Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA (2001) Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 220: 640-646.
6. Kinoshita M, McDannold N, Jolesz FA, Hynynen K (2006) Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci USA 103: 11719-11723.
7. Kinoshita M, McDannold N, Jolesz FA, Hynynen K (2006) Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound. Biochem Biophys Res Commun 340: 1085-1090.
8. Raymond SB, Treat LH, Dewey JD, McDannold NJ, Hynynen K, et al. (2008) Ultrasound enhanced delivery of molecular imaging and therapeutic agents in Alzheimer's disease mouse models. PLoS ONE 3: e2175.
9. Chopra R, Curiel L, Staruch R, Morrison L, Hynynen K (2009) An MRIcompatible system for focused ultrasound experiments in small animal models. Medical Physics 36: 1867-1874.
10. Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, et al. (2001) Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 276: 21562-21570.
11. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, et al. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14: 837-842.
12. Wilcock DM, Colton CA (2008) Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis 15: 555-569.
13. Opar A (2008) Mixed results for disease-modification strategies for Alzheimer's disease. Nat Rev Drug Discov 7: 717-718.
14. Bard F, Cannon C, Barbour R, Burke RL, Games D, et al. (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6: 916-919.
15. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, et al. (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98: 8850-8855.
16. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, et al. (2004) Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1: 24-34.
17. Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, et al. (2002) Passage of amyloid beta protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 23: 2223-2226.
18. Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, et al. (2003) Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 23: 3745-3751.
19. Sheikov N, McDannold N, Vykhodtseva N, Jolesz F, Hynynen K (2004) Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles. Ultrasound Med Biol 30: 979-989.
20. Sheikov N, McDannold N, Sharma S, Hynynen K (2008) Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium. Ultrasound Med Biol 34: 1093-1104.
21. Hynynen K, McDannold N, Vykhodtseva N, Raymond S, Weissleder R, et al. (2006) Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. J Neurosurg 105: 445-454.
22. Janus C, Welzl H, Hanna A, Lovasic L, Lane N, et al. (2004) Impaired conditioned taste aversion learning in APP transgenic mice. Neurobiol Aging 25: 1213-1219.
23. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, et al. (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408: 979-982.
24. Dasilva KA, Brown ME, McLaurin J (2009) Reduced oligomeric and vascular amyloid-beta following immunization of TgCRND8 mice with an Alzheimer's DNA vaccine. Vaccine 27: 1365-1376.
25. McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, et al. (2002) Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8: 1263-1269.
26. Frenkel D, Balass M, Solomon B (1998) N-terminal EFRH sequence of Alzheimer's beta-amyloid peptide represents the epitope of its anti-aggregating antibodies. J Neuroimmunol 88: 85-90.
27. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, et al. (2006) Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 12: 801-808.
28. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, et al. (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5: 452-457.
29. Braakman N, Matysik J, van Duinen SG, Verbeek F, Schliebs R, et al. (2006) Longitudinal assessment of Alzheimer's beta-amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging. J Magn Reson Imaging 24: 530-536.